Results 151 to 160 of about 3,492,883 (216)

Erratum: Aldehyde dehydrogenase 1A1 confers erlotinib resistance via facilitating the reactive oxygen species-reactive carbonyl species metabolic pathway in lung adenocarcinomas: Erratum. [PDF]

Theranostics, 2023
Lei HM, Zhang KR, Wang CH, Wang Y, Zhuang GL, Lu LM, Zhang J, Shen Y, Chen HZ, Zhu L.   +9 more
europepmc   +1 more source

Inhibition of miR-185-3p Confers Erlotinib Resistance Through Upregulation of PFKL/MET in Lung Cancers. [PDF]

Front Cell Dev Biol, 2021
Li K, Zhu X, Yuan C.
europepmc   +1 more source

Erratum: Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase: Erratum. [PDF]

Theranostics, 2021
Dong JK, Lei HM, Liang Q, Tang YB, Zhou Y, Wang Y, Zhang S, Li WB, Tong Y, Zhuang G, Zhang L, Chen HZ, Zhu L, Shen Y.   +13 more
europepmc   +1 more source

Revisiting Epidermal Growth Factor Receptor (EGFR) Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies. [PDF]

, 2019
PurposeTo date, evidence for tissue epidermal growth factor receptor (EGFR) overexpression as a biomarker for anti-EGFR therapies has been weak. We investigated the genomic landscape of EGFR amplification in blood-derived cell-free tumor DNA (cfDNA ...
Fanta, Paul T, Goodman, Aaron, Kato, Shumei, Kurzrock, Razelle, Lanman, Richard B, Lee, Suzanna, Lippman, Scott M, Mareboina, Manvita, Okamura, Ryosuke, Patel, Sandip P, Raymond, Victoria M, Schwab, Richard B, Sicklick, Jason K, Vu, Peter   +13 more
core   +1 more source

Quantitative modeling of tumor dynamics and development of drug resistance in non‐small cell lung cancer patients treated with erlotinib

CPT: Pharmacometrics & Systems Pharmacology
Insight into the development of treatment resistance can support the optimization of anticancer treatments. This study aims to characterize the tumor dynamics and development of drug resistance in patients with non‐small cell lung cancer treated with ...
Anyue Yin, G. D. Marijn Veerman, Johan G. C. vanHasselt, Christi M. J. Steendam, Hendrikus Jan Dubbink, Henk‐Jan Guchelaar, Lena E. Friberg, Anne‐Marie C. Dingemans, Ron H. J. Mathijssen, Dirk Jan A. R. Moes   +9 more
doaj   +1 more source

Correction: Targeting focal adhesion kinase overcomes erlotinib resistance in smoke induced lung cancer by altering phosphorylation of epidermal growth factor receptor. [PDF]

Oncoscience, 2021
Solanki HS, Raja R, Zhavoronkov A, Ozerov IV, Artemov AV, Advani J, Radhakrishnan A, Babu N, Puttamallesh VN, Syed N, Nanjappa V, Subbannayya T, Sahasrabuddhe NA, Patil AH, Prasad TSK, Gaykalova D, Chang X, Sathyendran R, Mathur PP, Rangarajan A, Sidransky D, Pandey A, Izumchenko E, Gowda H, Chatterjee A.   +24 more
europepmc   +1 more source

Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects [PDF]

, 2017
Diamond, Michael S, et al,, Govero, Jennifer   +2 more
core   +2 more sources

Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells [PDF]

, 2017
et al,, Ghasemi, Reza
core   +2 more sources

Harnessing nanotechnology for enhanced delivery of erlotinib: a dynamic duo in cancer treatment

Beni-Suef University Journal of Basic and Applied Sciences
Erlotinib is a reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that acts by inhibiting signaling pathways, resulting in the disruption of cancerous cell proliferation. Erlotinib is a promising anticancer agent mainly utilized
Rakesh Pahwa, Swati Saini, Jatin Chhabra, Rajat Goyal, Shobhit Kumar, Rajendra Awasthi, Harish Dureja   +6 more
doaj   +1 more source

Erratum: LHX6 Affects Erlotinib Resistance and Migration of EGFR-Mutant Non-Small-Cell Lung Cancer HCC827 Cells Through Suppressing Wnt/β-Catenin Signaling [Corrigendum]. [PDF]

Onco Targets Ther, 2021
europepmc   +2 more sources